GlassScriptPhysician profile
Ashlea J Hill
NPI 1235413329
$168,691.65
in general payments reported to CMS, 2019-2025
33 companies · $26K in 2025
The $26K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20K · 2022: $39K · 2023: $43K · 2024: $41K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $16K · Travel and Lodging: $13K · Food and Beverage: $9,943 · Consulting Fee: $9,175 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,462.94 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $15,529.00 |
| Travel and Lodging | $12,867.25 |
| Food and Beverage | $9,942.50 |
| Consulting Fee | $9,175.27 |
| Education | $146.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $41,463.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $35,308.77 | 2021-2025 | |
| Dexcom, INC. | $27,955.45 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $24,135.15 | 2021-2025 | |
| Lilly USA, LLC | $20,247.11 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $6,155.75 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Insulet Corporation | $3,046.86 | 2021-2025 | Omnipod |
| Eli Lilly and Company | $2,897.05 | 2023 | |
| Sanofi US Services INC. | $2,660.00 | 2025 | |
| Beta Bionics, INC. | $1,138.63 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Abbott Laboratories | $507.64 | 2021-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $454.59 | 2021-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $438.73 | 2021-2023 | Farxiga |
| Amgen INC. | $347.91 | 2021-2025 | Repatha, Repatha |
| Amarin Pharma, INC. | $330.63 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $298.80 | 2021-2025 | Minimed 780g |
| Corcept Therapeutics | $277.26 | 2021-2025 | Korlym |
| Cequr Corporation | $168.83 | 2025 | Cequr Simplicity |
| Averitas Pharma INC. | $168.55 | 2023-2025 | Qutenza |
| Merck Sharp & Dohme LLC | $111.74 | 2021-2023 | Steglatro |
| Tandem Diabetes Care, INC. | $104.95 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $99.63 | 2021-2025 | Gvoke Hypopen |
| Grt US Holding, INC. | $93.59 | 2022 | |
| Sequel Med Tech, LLC | $58.05 | 2025 | Twiist |
| Alkermes, INC. | $51.54 | 2021 | |
| Evoke Pharma, INC. | $34.51 | 2023-2025 | Gimoti |
| Kowa Pharmaceuticals America, INC. | $29.98 | 2023 | Livalo |
| Mannkind Corporation | $21.64 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.95 | 2023 | |
| Amphastar Pharmaceuticals, INC. | $18.49 | 2025 | Baqsimi |
| Abbvie INC. | $17.70 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.75 | 2022 | |
| Horizon Therapeutics Plc | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashlea Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.